According to the WHO, antibiotic resistance has become one of the biggest health threats to humanity. By 2050, if no alternatives to antibiotics are found, about 10 million people will die each year. Micreos has developed such an alternative with Staphefekt. It is a so-called endolysin: an enzyme that kills only harmful bacteria and leaves the beneficial bacteria intact. The active substance is effective against Staphylococcus aureus, including the methylin resistant variant (MRSA). Advantage: Unlike antibiotics, the body's microbiome is not spared. In addition, resistances are not expected.
Based on this technology, the company is developing a range of pharmaceutical products. Among these are the product against MRSA in wound infections and the product against certain forms of skin cancer that cause bacteria. At the same time, Micreos sells various OTC products under the Gladskin brand for people with inflammatory skin diseases such as atopic dermatitis, acne or rosacea.
With EU funding, the company aims to expand endolysin production, perform placebo-controlled double-blind studies and facilitate access to Gladskin products in Europe. "With the EU grant, we can further develop our technology to reach our full potential. It gives us an opportunity to help even more people, ”says Mark Offerhaus chief.